{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:45:17Z","timestamp":1753875917217,"version":"3.41.2"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This case study describes a female patient in her late 70s who developed autoimmune cholangitis a year after finishing 35 cycles of pembrolizumab for the treatment of her non-small cell lung cancer. The diagnosis was initially missed and delayed; the patient\u2019s agoraphobia and the COVID-19 pandemic were noted as contributing factors.<\/jats:p>","DOI":"10.1093\/bjrcr\/uaae040","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T15:46:58Z","timestamp":1730476018000},"source":"Crossref","is-referenced-by-count":0,"title":["Delayed onset autoimmune cholangitis in a patient treated with pembrolizumab"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2987-9613","authenticated-orcid":false,"given":"Joshua","family":"Newington","sequence":"first","affiliation":[{"name":"Addenbrooke\u2019s Hospital, University of Cambridge , Cambridge CB2 0SP,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Patterson","sequence":"additional","affiliation":[{"name":"Department of Oncology, West Suffolk Hospital , Bury Saint Edmunds IP33 2QZ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Department of Radiology, West Suffolk Hospital , Bury Saint Edmunds IP33 2QZ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"2024110803105040300_uaae040-B1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-015-0078-9","article-title":"Pembrolizumab","volume":"3","author":"Khoja","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2024110803105040300_uaae040-B2","doi-asserted-by":"crossref","first-page":"9016","DOI":"10.1200\/JCO.2016.34.15_suppl.9016","article-title":"Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C","volume":"34(15_suppl)","author":"Gadgeel","year":"2016","journal-title":"JCO"},{"key":"2024110803105040300_uaae040-B3","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001"},{"issue":"3","key":"2024110803105040300_uaae040-B4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2024110803105040300_uaae040-B5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"2024110803105040300_uaae040-B6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis [published correction appears in JAMA Oncol. 2018;4(12):1792]","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"28","key":"2024110803105040300_uaae040-B7","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.3748\/wjg.v28.i28.3732","article-title":"Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: a case report","volume":"28","author":"Tanaka","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"2","key":"2024110803105040300_uaae040-B8","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.cgh.2020.11.048","article-title":"Pembrolizumab-induced sclerosing cholangitis","volume":"20","author":"Tahboub Amawi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2024110803105040300_uaae040-B9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/jjco\/hyaa201","article-title":"Pembrolizumab-related sclerosing cholangitis manifested by a pruned-tree appearance of the bile ducts","volume":"51","author":"Takinami","year":"2021","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"2024110803105040300_uaae040-B10","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/hepr.13329","article-title":"Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work","volume":"49","author":"Koya","year":"2019","journal-title":"Hepatol Res"},{"key":"2024110803105040300_uaae040-B11","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33(1S Suppl 1)","author":"Pi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["BJR|Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjrcr\/advance-article-pdf\/doi\/10.1093\/bjrcr\/uaae040\/60412656\/uaae040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjrcr\/article-pdf\/10\/6\/uaae040\/60500604\/uaae040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjrcr\/article-pdf\/10\/6\/uaae040\/60500604\/uaae040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T03:11:13Z","timestamp":1731035473000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjrcr\/article\/doi\/10.1093\/bjrcr\/uaae040\/7863291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjrcr\/uaae040","relation":{},"ISSN":["2055-7159"],"issn-type":[{"type":"electronic","value":"2055-7159"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,11,1]]},"article-number":"uaae040"}}